Therefore, further studies of TK1 may improve our understanding of HCC immunobiology and could help to break immune tolerance in HCC with poor immunogenicity, thus providing a theoretical basis for the development of anti-TK1 immunotherapy in this tumor type. This evidence concerns the gene TK1 and neoplasm.